Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Novo Nordisk announces results from SCALE Obesity and Pre-diabetes phase 3a trial


Thursday, 15 May 2014 08:00pm EDT 

Novo Nordisk A/S:Presents results from SCALE Obesity and Pre-diabetes phase 3a trial.After 56 weeks of treatment, liraglutide 3 mg in combination with diet and exercise, provided greater weight loss of 8 pct from baseline compared to 2.6 pct with placebo (p<0.0001).All treatment groups included a reduced-calorie diet and increased physical activity.The proportion of adults achieving weight loss of 5 pct or more of their baseline body weight was 64 pct for liraglutide 3 mg treatment compared to 27 percent for placebo (p<0.0001).33 pct of adults treated with liraglutide 3 mg achieved weight loss greater than 10 pct of their baseline body weight compared to 10 pct for placebo (p<0.0001).Treatment with liraglutide 3 mg reduced waist circumference by –8.19 cm, compared to –3.94 cm with placebo (p<0.0001).Treatment with liraglutide 3 mg improved blood glucose levels, blood pressure and lipids levels.Reported side effects were gastrointestinal (nausea and diarrhoea), which were mild to moderate, occurred shortly after liraglutide initiation, and were transient.Incidences of gallbladder disorders and pancreatitis were low but higher than in placebo-treated individuals.Gallbladder disorders were reported as 2.7 events per 100 patient-years of exposure (PYE) with liraglutide 3 mg treatment compared to 1.0 events per 100 PYE for placebo.Pancreatitis was reported as 0.3 events per 100 PYE with liraglutide 3 mg compared to 0.1 events per 100 PYE with placebo. 

Company Quote

46.16
2.65 +6.09%
1:01pm EDT